share_log

Otonomy (NASDAQ:OTIC) Earns Hold Rating From Analysts at StockNews.com

Otonomy (NASDAQ:OTIC) Earns Hold Rating From Analysts at StockNews.com

Otonomy（纳斯达克股票代码：OTIC）获得StockNews.com分析师的持有评级
kopsource ·  2022/12/27 01:21

StockNews.com started coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report sent to investors on Saturday morning. The firm issued a hold rating on the biopharmaceutical company's stock.

斯托克新闻网在周六上午发给投资者的一份研究报告中开始对Otmey(纳斯达克：One-Get Rating)的股票进行报道。该公司对这家生物制药公司的股票发布了持有评级。

Separately, Piper Sandler lowered shares of Otonomy from an overweight rating to a neutral rating and dropped their price target for the company from $3.00 to $0.50 in a research note on Thursday, October 13th.

另外，派珀·桑德勒在10月13日(星期四)的一份研究报告中将Otmey的股票评级从增持下调至中性，并将该公司的目标价从3.00美元下调至0.50美元。

Get
到达
Otonomy
眼球运动
alerts:
警报：

Otonomy Price Performance

高性价比

Shares of Otonomy stock opened at $0.07 on Friday. The firm has a market capitalization of $4.23 million, a P/E ratio of -0.10 and a beta of 1.31. Otonomy has a 52 week low of $0.06 and a 52 week high of $2.59. The firm's 50 day moving average is $0.11 and its two-hundred day moving average is $0.68.

上周五，Otmey的股票开盘报0.07美元。该公司的市值为423万美元，市盈率为-0.10，贝塔系数为1.31。Otomy的52周低点为0.06美元，52周高位为2.59美元。该公司的50日移动均线切入位在0.11美元，200日移动均线切入位在0.68美元。

Hedge Funds Weigh In On Otonomy

对冲基金对Otmey的看法

Hedge funds have recently added to or reduced their stakes in the stock. Requisite Capital Management LLC acquired a new stake in shares of Otonomy in the third quarter valued at approximately $44,000. Two Sigma Investments LP boosted its holdings in shares of Otonomy by 129.2% in the third quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 80,153 shares during the period. Lynx1 Capital Management LP boosted its holdings in shares of Otonomy by 7,609.6% in the third quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock valued at $682,000 after acquiring an additional 2,282,880 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Otonomy in the third quarter valued at approximately $1,621,000. Finally, State Street Corp boosted its holdings in shares of Otonomy by 5.1% in the first quarter. State Street Corp now owns 182,239 shares of the biopharmaceutical company's stock valued at $437,000 after acquiring an additional 8,839 shares during the period. 41.23% of the stock is currently owned by hedge funds and other institutional investors.
对冲基金最近增持或减持了该股。必备资本管理公司在第三季度收购了Otmey公司的新股份，价值约为4.4万美元。Two Sigma Investments LP在第三季度增持了129.2%的Otomy股票。Two Sigma Investments LP现在拥有这家生物制药公司142,183股票，价值42,000美元，在此期间又购买了80,153股票。Lynx1 Capital Management LP在第三季度将其持有的Otmey股票增加了7609.6%。Lynx1 Capital Management LP在此期间额外收购了2,282,880股，现在拥有这家生物制药公司2,312,880股股票，价值682,000美元。Point72 Asset Management L.P.在第三季度收购了Otmey的新股份，价值约1,621,000美元。最后，道富银行在第一季度增持了Otmey的股票5.1%。道富集团目前拥有182,239股这家生物制药公司的股票，价值437,000美元，在此期间又购买了8,839股。41.23%的股票目前由对冲基金和其他机构投资者持有。

Otonomy Company Profile

Otmey公司简介

(Get Rating)

(获取评级)

Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.

Otomy，Inc.是一家生物制药公司，在美国开发神经学疗法。该公司提供治疗耳鸣的N-甲基-D-天冬氨酸受体拮抗剂Gacycldine的持续暴露制剂OTO-313，以及治疗耳鸣的脑源性神经营养因子持续暴露制剂OTO-413，该制剂处于第二阶段临床试验，用于修复耳蜗突触和治疗噪音中语音听力困难。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on Otonomy (OTIC)
  • Three Healthcare Penny Stocks to Watch In The New Year
  • Southwest Airlines Stock, There is a Lot to Love
  • MarketBeat: Week in Review 12/19 – 12/23
  • These Steelmakers Deserve A Place On Your 2023 Watch List
  • Inflation Cools, Where Does The S&P 500 Go Now
  • 免费获取StockNews.com关于OTMy的研究报告(OTIC)
  • 新年值得关注的三只医疗保健便士股
  • 西南航空公司股票，有很多值得爱的东西
  • MarketBeat：回顾一周12/19-12/23
  • 这些钢铁制造商理应在2023年观察名单上占有一席之地
  • 通胀降温，标普500指数何去何从

Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.

接收《Otmey Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对Otmey及相关公司评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发